GlassScriptPhysician profile
Zhihao Dai
NPI 1134175565
$7,582.29
in general payments reported to CMS, 2019-2025
49 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.73 · 2021: $514 · 2022: $1,117 · 2023: $1,731 · 2024: $1,950 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,934.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $933.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $845.67 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Radius Health, INC. | $467.30 | 2023-2025 | Tymlos |
| Corcept Therapeutics | $402.69 | 2022-2025 | Korlym |
| Amgen INC. | $388.91 | 2021-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $327.21 | 2021-2025 | |
| Exact Sciences Corporation | $299.02 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $265.42 | 2021-2025 | Linzess, Viberzi, Ubrelvy |
| Mannkind Corporation | $235.10 | 2022-2025 | Afrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.53 | 2021-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $187.07 | 2021-2024 | |
| Tandem Diabetes Care, INC. | $181.26 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $176.53 | 2022-2025 | Cequr Simplicity |
| Inspire Medical Systems, INC. | $165.94 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $162.46 | 2022-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $158.28 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.43 | 2022-2025 | Jardiance |
| Ibsa Pharma INC. | $146.47 | 2022-2025 | Tirosint, Licart, Flector |
| Insulet Corporation | $133.27 | 2023-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $129.08 | 2021-2025 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $122.62 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $116.62 | 2023-2025 | Yorvipath |
| Kowa Pharmaceuticals America, INC. | $109.45 | 2021-2023 | Livalo |
| Astrazeneca Pharmaceuticals LP | $105.73 | 2022-2025 | Farxiga, Airsupra |
| Sanofi Pasteur INC. | $103.26 | 2020-2025 | |
| Tolmar, INC. | $99.95 | 2023-2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $85.56 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $72.09 | 2022-2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $64.25 | 2022-2025 | Veozah |
| Madrigal Pharmaceuticals | $59.56 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $54.52 | 2021-2022 | |
| Dexcom, INC. | $52.44 | 2024 | Dexcom G6 Transmitter |
| Embecta Corp. | $52.26 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Beta Bionics, INC. | $50.88 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Verity Pharmaceuticals INC. | $43.43 | 2025 | Tlando |
| Ascensia Diabetes Care US INC. | $43.22 | 2025 | |
| Kyowa Kirin, INC. | $41.00 | 2024-2025 | Crysvita |
| Zealand Pharma US, INC. | $40.80 | 2021-2022 | |
| Vivus LLC | $38.09 | 2022 | |
| Neurocrine Biosciences, INC. | $37.55 | 2025 | |
| Antares Pharma, INC. | $31.04 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $26.12 | 2025 | Strensiq |
| Dynavax Technologies Corporation | $25.41 | 2024 | Heplisav-B |
| Avvisto Therapeutics, LLC | $24.90 | 2025 | Cycloset |
| Grt US Holding, INC. | $22.93 | 2021 | |
| Halozyme INC | $22.04 | 2023 | |
| Alvogen INC | $21.78 | 2025 | Teriparatide |
| Boston Scientific Corporation | $19.85 | 2024 | Watchman Flx |
| Idorsia Pharmaceuticals US INC | $18.45 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhihao Dai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.